Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-16T16:20:13.757Z Has data issue: false hasContentIssue false

Impact of empiric antibiotics on risk of Clostridioides difficile—a causal inference observational analysis

Published online by Cambridge University Press:  12 February 2025

Matthew A. Pappas*
Affiliation:
Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USACenter for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USACOVID-19 Consortium of HCA Healthcare and Academia for Research Generation, Nashville, TN, USA
Shoshana J. Herzig
Affiliation:
COVID-19 Consortium of HCA Healthcare and Academia for Research Generation, Nashville, TN, USADepartment of Medicine, Division of General Medicine, and Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
Andrew D. Auerbach
Affiliation:
COVID-19 Consortium of HCA Healthcare and Academia for Research Generation, Nashville, TN, USADepartment of Hospital Medicine, University of California, San Francisco, CA, USA
Abhishek Deshpande
Affiliation:
Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA
Eunice Blanchard
Affiliation:
COVID-19 Consortium of HCA Healthcare and Academia for Research Generation, Nashville, TN, USAInfection Control and Hospital Epidemiology, HCA Healthcare, Nashville, TN, USA
Michael B. Rothberg
Affiliation:
Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA
*
Corresponding author: Matthew A. Pappas; Email: pappasm@ccf.org

Abstract

Background:

Clostridioides difficile infection (CDI) is a common and often nosocomial infection associated with increased mortality and morbidity. Antibiotic use is the most important modifiable risk factor, but many patients require empiric antibiotics. We estimated the increased risk of hospital-onset CDI with one daily dose-equivalent (DDE) of various empiric antibiotics compared to management without that daily dose-equivalent.

Methods:

Using a multicenter retrospective cohort of adults admitted between March 2, 2020 and February 11, 2021 for the treatment of SARS-CoV-2, we used a series of three-level logistic regression models to estimate the probability of receiving each of several antibiotics of interest. For each antibiotic, we then limited our data set to patient-days at intermediate probability of receipt and used augmented inverse-probability weighted models to estimate the average treatment effect of one daily dose-equivalent, compared to management without that daily dose-equivalent, on the probability of hospital-onset CDI.

Results:

In 24,406 patient-days at intermediate probability of receipt, parenteral vancomycin increased risk of hospital-onset CDI, with an average treatment effect of 0.0096 cases per daily dose-equivalent (95% CI: 0.0053—0.0138). In 38,003 patient-days at intermediate probability of receipt, cefepime also increased subsequent CDI risk, with an estimated effect of 0.0074 more cases per daily dose-equivalent (95% CI: 0.0022—0.0126).

Conclusions:

Among common empiric antibiotics, parenteral vancomycin and cefepime appeared to increase risk of hospital-onset CDI. Causal inference observational study designs can be used to estimate patient-level harms of interventions such as empiric antimicrobials.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Patient and hospitalization characteristics

Figure 1

Table 2.Characteristics of patient-days included in analyses

Figure 2

Table 3.Absolute treatment effect of one daily dose-equivalent of each antibiotic on the rate of hospital-onset C. difficile infection

Supplementary material: File

Pappas et al. supplementary material

Pappas et al. supplementary material
Download Pappas et al. supplementary material(File)
File 6.4 MB